Astec Q4 FY26 Income up 34% to ₹161.3 Cr; EBITDA up 87% to ₹11.8 Cr

Astec LifeSciences Ltd announced its consolidated financial results for Q4 and the full financial year ended March 31, 2026. For Q4 FY26, the company reported a consolidated total income of ₹161.3 crore, a 34% increase year-on-year, and consolidated EBITDA of ₹11.8 crore, an 87% rise from Q4 FY25. The loss after tax for the quarter reduced to ₹7.7 crore from ₹16.1 crore in the prior year. For the full FY26, consolidated total income grew 17.1% to ₹453.2 crore, and the company achieved an EBITDA breakeven of ₹0.5 crore, a significant improvement from an EBITDA loss of ₹60.6 crore in FY25. The loss after exceptional items and tax for FY26 was ₹80.9 crore, down from ₹134.7 crore in FY25. The Chairperson attributed Q4's strong performance to improved volumes in both Enterprise and Contract Manufacturing segments.